drugset / Trial / NCT01865188

Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension

NCT01865188

Phase 3 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the blood pressure lowering effect and safety of LCZ696 when given alone and in combination with amlodipine in patients with essential hypertension.

Timeline

Start
2014-04
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Amlodipine Other / unclassified 10 mg
Subject LCZ696 Unknown 200 mg
Subject LCZ696 Unknown 400 mg